Intuitive Surgical IncACA subsidy expiration reduces patient coverage, slowing US da Vinci procedure growth below expectations.
Intuitive Surgical shares fell more than 12% before the bell on July 17 after the company acknowledged that the expiration of enhanced Affordable Care Act subsidies is affecting demand for elective procedures performed with its da Vinci surgical robots. US da Vinci procedure growth slowed to roughly 12% in the second quarter, below the company’s expectations at the start of the year, with CEO David Rosa noting that fluctuating patient coverage and premium dynamics influence when patients seek care. The selloff occurred despite Intuitive beating consensus estimates for revenue, earnings, system placements, and procedure growth in the same quarter, and maintaining its global procedure-growth forecast. The company’s results appear to support HCA Healthcare’s earlier warning of lower surgical demand and rising uninsured patients, contradicting Abbott’s view that blaming industry-wide weakness on ACA disenrollment was a flawed assumption. Stifel cut its price target on Intuitive to $550 from $670 while keeping a Buy rating, and the stock’s forward P/E ratio has fallen to about 33x, near the low end of its five-year range and roughly in line with the medical device peer group average.
Intuitive Surgical IncACA subsidy expiration reduces patient coverage, slowing US da Vinci procedure growth below expectations.
Stifel Financial CorporationStifel cut its price target on Intuitive Surgical to $550 from $670, but kept a Buy rating.
Abbott Laboratories
HCA Healthcare, Inc.